Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Head and Neck Cancer Therapeutics Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
The latest research report on the global head and neck cancer therapeutics market has been published, providing a comprehensive analysis of the industry's current state and future growth prospects. The report highlights the market expansion from $1.55 billion in 2023 to an anticipated $2.32 billion by 2027, growing at a CAGR of 10.7%.
The head and neck cancer therapeutics market is driven by the increasing prevalence of the disease globally. Advancements in diagnostics and treatment options, including the rise of novel therapeutics, are significant trends that are set to bolster market growth. Notably, North America currently stands as the largest market, while Asia-Pacific is projected to experience the fastest growth during the forecast period. This industry research report presents a detailed overview of market dynamics, encompassing key therapeutic segments such as programmed cell death (PD) inhibitors, microtubule inhibitors, and epidermal growth factor receptor (EGFR) inhibitors. The report delves into the various applications of these therapeutics, including use in treatments like surgery, radiation therapy, chemotherapy, and immunotherapy.
Key Report Findings
- Expanding prevalence of head and neck cancers globally is propelling the demand for effective therapeutics.
- Development of novel therapies, such as IAP antagonists and PD inhibitors, is a key trend that is anticipated to drive the head and neck cancer therapeutics market.
- North America leads the market share, while Asia-Pacific is poised for rapid growth.
- Technological advancements in treatment protocols and increased R&D investments are further contributing to market growth.
A selection of companies mentioned in this report includes
- Pfizer Inc.
- F Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- AbbVie Inc.
- Bayer AG
- Novartis AG
- Sanofi Aventis LLC
- Bristol-Myers-Squibb Company
- AstraZeneca PLC
- GlaxoSmithKline plc.
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Gilead Sciences Inc.
- Amgen Inc.
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Astellas Pharma Inc.
- Daiichi Sankyo Company Limited
- Eisai Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Incyte Corporation
- Ono Pharmaceutical Co. Ltd.
- Kyowa Kirin Co. Ltd.
- Hikma Pharmaceuticals PLC
- Clinigen Group plc.
- Ligand Pharmaceuticals
- Acceleron Pharma Inc.
- Taiho Pharmaceutical Co. Ltd.
- Boston Biomedical Inc.
- AB Science SA.
For more information about this report visit https://www.researchandmarkets.com/r/uuxolv
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
